Skip to main content

Garth S Herbert, MD

Assistant Professor of Surgery
Office: 3404 Wake Forest Rd, Suite 303, Raleigh, NC 27609

Education and Training

  • Complex General Surgical Oncology Fellow, Surgery, Memorial Sloan-Kettering Cancer Center, 2013 - 2015
  • General Surgery Resident, Surgery, Madigan Army Medical Center, 2003 - 2009
  • M.D., Yale University School of Medicine, 2003
  • B.S., United States Military Academy, 1995

Publications

Giannis, Dimitrios, Marcelo Cerullo, Dimitrios Moris, Kevin N. Shah, Garth Herbert, Sabino Zani, Dan G. Blazer, Peter J. Allen, and Michael E. Lidsky. “Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors.” Cancers (Basel) 13, no. 3 (February 1, 2021). https://doi.org/10.3390/cancers13030547.

Full Text

Chick, Robert Connor, Annelies T. Hickerson, Guy Travis Clifton, Phillip M Kemp Bohan, Tommy A. Brown, Jessica L. Cindass, John W. Myers, et al. “Abstract 6536: Safety and efficacy of autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccination in combination with systemic therapies in patients with metastatic melanoma.” In Clinical Research (Excluding Clinical Trials). American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.am2020-6536.

Full Text

Brown, Tommy A., Kevin Byrd, Timothy J. Vreeland, Guy T. Clifton, Doreen O. Jackson, Diane F. Hale, Garth S. Herbert, et al. “Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.” Cancer Med 8, no. 10 (August 2019): 4678–87. https://doi.org/10.1002/cam4.2378.

Full Text

Clifton, G Travis, Kaitlin M. Peace, Jarrod P. Holmes, Timothy J. Vreeland, Diane F. Hale, Garth S. Herbert, Jennifer K. Litton, et al. “Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.” Clin Immunol 201 (April 2019): 48–54. https://doi.org/10.1016/j.clim.2019.02.011.

Full Text

Herbert, Garth S., Timothy J. Vreeland, Guy T. Clifton, Julia M. Greene, Doreen O. Jackson, Mark O. Hardin, Diane F. Hale, et al. “Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.” Vaccine 36, no. 23 (May 31, 2018): 3247–53. https://doi.org/10.1016/j.vaccine.2018.04.078.

Full Text

Hardin, Mark O., Timothy J. Vreeland, Guy T. Clifton, Diane F. Hale, Garth S. Herbert, Julia M. Greene, Doreen O. Jackson, et al. “Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine.” Immunotherapy 10, no. 5 (April 2018): 373–82. https://doi.org/10.2217/imt-2017-0114.

Full Text

Herbert, Garth, Giorgos C. Karakousis, Edmund K. Bartlett, Salman Zaheer, Danielle Graham, Brian J. Czerniecki, Douglas L. Fraker, Charlotte Ariyan, Daniel G. Coit, and Mary S. Brady. “Transected thin melanoma: Implications for sentinel lymph node staging.” J Surg Oncol 117, no. 4 (March 2018): 567–71. https://doi.org/10.1002/jso.24930.

Full Text

Berry, John, Timothy Vreeland, Alfred Trappey, Diane Hale, Kaitlin Peace, Joshua Tyler, Avery Walker, et al. “Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.” Expert Rev Clin Immunol 13, no. 3 (March 2017): 235–45. https://doi.org/10.1080/1744666X.2016.1226132.

Full Text

Pages